Market Access News | pharmaphorum

News

NICE relents on Takeda colorectal cancer drug Fruzaqla

Colorectal cancer patients could soon have access via the NHS to a targeted oral drug that can give them more precious time with their loved ones.

News

The NHS 10 Year Plan arrives – what are the highlights?

After months of preparation and a drip-feed of some of its key features, the UK government has raised the curtain on its new 10-year plan for the NHS.

News

Dizal set to bring lung cancer drug Zegfrovy to US

Dizal gets US approval for an oral therapy for EGFR exon 20-mutated NSCLC, offering some patients an alternative to J&J's intravenous Rybrevant.

News

Regeneron gets long-awaited FDA okay for myeloma drug

Regeneron's bid to join the crowded US market for BCMA-targeted bispecific antibodies for multiple myeloma has finally been realised.

News

UK government reveals neighbourhood healthcare delivery plan

The UK government's Neighbourhood Health Service is central to the NHS 10 Year Plan - but can it deliver real change?

News

New passport 'will speed medtech rollout in NHS'

The UK has revealed a new 'innovator passport' designed to accelerate the rollout of proven medtech in the NHS.

NICE relents on Takeda colorectal cancer drug Fruzaqla

The NHS 10 Year Plan arrives – what are the highlights?

Dizal set to bring lung cancer drug Zegfrovy to US

Regeneron gets long-awaited FDA okay for myeloma drug

UK government reveals neighbourhood healthcare delivery plan

New passport 'will speed medtech rollout in NHS'

Lilly partners with Hims & Hers on obesity drug sales

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks